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Abstract 
 
Background: Youth who are being treated with antipsychotic medications are at increased risk for the development of obesity 
and type 2 diabetes. Behavioral weight loss treatments show promise for reducing obesity and diabetes risk among adults 
treated with these drugs, but such treatments have not previously been studied in youth.  
Objective: We describe a rationale for behavioral weight loss intervention for high-weight youth being treated with 
antipsychotic medications. We report behavioral, anthropomorphic, and metabolic findings from a case series of obese 
adolescents taking antipsychotic medications who participated in a short-term, family-based behavioral weight loss 
intervention.  
Methods: We adapted the Traffic Light Plan, a 16-week family-based weight loss intervention that promotes healthy energy 
balance using the colors of the traffic light to categorize the nutritional value of foods and the intensity of physical activity. 
We then added a social and ecological framework to address health behavior change in multiple social contexts. The 
intervention was administered to three obese adolescents with long-term antipsychotic medication exposure. The efficacy of 
the intervention was evaluated with a battery of anthropomorphic and metabolic assessments, including weight, body mass 
index percentile, whole body adiposity, liver fat content, and fasting plasma glucose and lipid levels. Participants and their 
parents also filled out a treatment satisfaction questionnaire after study completion. 
Results: Two boys and one girl, all of whom were 14 years old, participated in this study. All three participants attended all 
16 sessions of the intervention and experienced beneficial changes in adiposity, fasting lipid levels, and liver fat content 
associated with weight stabilization or weight loss. Adolescents and their parents all reported a high level of satisfaction with 
the treatment.  
Conclusions: Family-based behavioral weight loss treatment can be feasibly delivered and is acceptable to youth taking 
antipsychotic medications and their families. Randomized controlled trials are needed to fully evaluate the effectiveness and 
acceptability of these treatments for these individuals.  
 
ClinicalTrials.gov Identifier: NCT01222494 
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Introduction 
Pediatric obesity is a rising public health concern that 
is associated with the early onset of cardiovascular 
disease risk conditions such as fatty liver and diabetes 
(1-3). Children with psychiatric conditions may be 
particularly vulnerable to the development of obesity 
and related adverse health conditions (4). The 
increased risk for obesity in psychiatric populations 
is exacerbated by the use of second-generation 
antipsychotic medications (hereafter referred to as 
antipsychotics), which increase the risk for weight gain 
and related adverse changes in lipid and glucose 
metabolism (5,6). Youth who are being treated with 
antipsychotics are more than twice as likely as 
children in the general population to develop obesity-
related cardiometabolic risk conditions like diabetes, 
hypertension, and hyperlipidemia (7-9). For 
populations in which obesity is the result of medical 
treatments, first-line treatment strategies include the 
discontinuation of agents that cause or contribute to 
weight gain and substitution with a lower-risk agent 
if one is available (10; p. 2489). Although 
antipsychotic discontinuation in youth is associated 
with weight loss, it may come at the price of 
psychiatric symptom recurrence, including aggressive 
or self-injurious behavior (11-13). Therefore, it is 
imperative to identify strategies to mitigate weight 
gain when maintenance treatment with 
antipsychotics is necessary. 
The putative mechanisms of antipsychotic-induced 
weight gain are related to the medications’ 
combination of dopamine blockade at D2 receptors, 
antagonism or inverse agonism at 5HT2C serotonin 
receptors, antagonism at 5HT2A serotonin receptors, 
antagonism at alpha-1A adrenergic receptors, and 
especially antagonism at histamine-1 receptors (14). 
Blocking the activity of dopamine—particularly in 
the subcortical, limbic, and striatal areas of the 
brain—leads to an upregulation of postsynaptic 
receptors as well as increased dopamine within the 
synaptic cleft, which may create a “reward 
deficiency” syndrome that prevents satiety (15). 
Serotonin receptor inverse agonism or antagonism 
may lead to decreased satiety and hyperphagia 
(16,17). Finally, weight gain has long been associated 
with centrally active drugs that have high affinity for 
the histamine-1 receptor, and H1 antagonism is 
known to increase feeding (18,19) and sedation, with 
predictable reductions in caloric expenditure (14). 
Although treatment-related weight gain is 
pharmacologically driven, it could potentially be 
addressed by behavioral strategies that affect 
decreased satiety, increased food seeking, and 
sedentary behavior. Core principles of behavioral 
weight loss that may impact satiety and activity level 
typically involve food and activity substitutions, with 
progressive goal setting and reinforcement to reach 
the identified terminal health behavior targets and to 
change food and activity preferences. 
Intensive behavioral weight loss and lifestyle 
modification programs have been successfully 
adapted for use in adults with psychotic disorders and 
other severe mental illnesses who are taking 
antipsychotics (20-22). One particularly successful 
weight loss intervention has incorporated 
psychosocial and cognitive rehabilitation strategies 
into a health education framework in a setting in 
which patients received mental health care and social 
support (23)). Social ecological approaches to health 
behavior change in psychiatric populations consider 
the adjustment, coping, and adaptive functioning of 
the individual within a social and cultural context 
(24). This focus on facilitating the individual’s 
involvement in and impact on the environment as an 
agent of change is thought to enhance the likelihood 
of the sustained improvement of health behaviors. 
Social ecological models of pediatric health behavior 
change include the family as an integral part of the 
child’s immediate environment and promote the 
development of parent-facilitated social networks 
that support health behavior change and that address 
social barriers to engaging in health behavior change 
(25,26). Weight loss treatments that make use of a 
social ecological approach to health behavior change 
may be ideally suited to promoting health behavior 
change in mentally ill youth, because psychosocial 
barriers to participation may be more pronounced as 
compared with populations of non-psychiatrically ill 
individuals. Family is part of the first and perhaps 
most important layer of social ecology in the lives of 
children, and thus social ecological approaches that 
focus on the involvement of social supports, 
including family, may be of primary importance for 
individuals who face psychiatric illnesses as barriers 
to health behavior change. 
Family-based behavioral weight loss treatment 
(FBT) is considered a first-line treatment for the 
management of pediatric obesity (27,28). Published 
meta-analyses have documented that such 
interventions lead to improved weight outcomes 
among children and adolescents (29,30). However, 
these reports also highlight the need for studies that 
evaluate treatment-related changes in metabolic 
parameters and that test strategies for enhancing real-
world intervention delivery, particularly in at-risk 
populations such as individuals with psychiatric 
illnesses who are treated with antipsychotics (31). To 
our knowledge, two studies that included behavioral 
weight loss as part of the study design have been 
conducted in overweight or obese youth treated with 
antipsychotics (32,33). However, we are aware of no 
published studies evaluating the feasibility and 
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efficacy of family-based behavioral weight loss 
interventions in this population nor of any studies 
that measure the impact of such interventions on 
metabolic health outcomes.  
The present report describes a modified FBT 
approach to weight loss among youth taking 
antipsychotics and reports on the first three 
participants in a randomized controlled trial to 
evaluate the efficacy of FBT for weight loss in youth 
between the ages of 6 and 18 years treated with 
antipsychotics. The design of this study involves 
delivering weekly FBT to youth with psychiatric 
illnesses treated with antipsychotics as compared 
with otherwise healthy but overweight or obese 
youth, with a monthly standard-of-care reference 
group treated with antipsychotics. The primary 
outcomes of this study include gold-standard 
measures of body composition and metabolism: 
changes in total percentage of body fat and liver fat, 
measured respectively via dual energy X-ray 
absorptiometry and magnetic resonance 
spectroscopy; common clinical measures, such as 
body mass index (BMI) and BMI percentile; vital 
signs; and fasting plasma lipid and glucose values. We 
hypothesize that individuals treated with 
antipsychotic agents can successfully participate in 
behavioral weight loss treatment without adverse 
weight or metabolic outcomes. Here, we describe the 
weekly FBT program adapted for use in youth treated 
with antipsychotics to incorporate a social ecological 
approach, and we report changes in weight and other 
measures of metabolic health in the initial three 
patients who completed the weight loss treatment. 
 
Participants 
Three adolescent participants were recruited from 
the Washington University School of Medicine Child 
and Adolescent Psychiatry Outpatient Clinic. In all 
cases, the participant’s pediatrician or primary care 
provider was notified of study participation and 
provided medical assent. Outpatient weights and 
heights collected during the year prior to study 
enrollment were obtained for all participants from 
their primary care provider or treating psychiatrist. 
Inclusion criteria for the overall study included the 
following:  
1) overweight (BMI percentile ≥85) or obese 
(BMI percentile ≥95) youth between the ages 
of 6 and 18 years;  
2) any Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, Text Revision diagnosis;  
3) at least 6 continuous months of treatment 
with antipsychotics;  
4) documented weight gain that was greater than 
expected (e.g., crossing a percentile line on the 
BMI growth chart);  
5) evidence of psychiatric stability (i.e., no 
inpatient hospitalizations during the previous 
6 months and no changes in psychotropic 
medication doses for 4 weeks);  
6) consenting adult caregiver willing to 
participate in the study; and 
7) ability to provide assent for participation as 
evidenced by documented or clinically 
estimated intelligence quotient of 70 or higher.  
 
Exclusion criteria included the following:  
1) youth who were not overweight or obese by 
BMI percentile;  
2) age outside the specified range of 6 to 18 years;  
3) no presence of any Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text 
Revision diagnosis;  
4) less than 6 months of antipsychotic treatment;  
5) active suicidality or substance use disorders;  
6) lack of psychiatrically stability and/or 
antipsychotic treatment deemed in-
appropriate;  
7) no consenting adult caregiver able to 
participate in the study; and  
8) estimated or documented intelligence quotient 
of less than 70.  
 
Concurrent treatment with selective serotonin 
reuptake inhibitors and attention-deficit/ 
hyperactivity disorder medications (including 
stimulants, Atomoxetine, or alpha-agonist agents 
below a total daily dose of 2 mg/kg methylphenidate 
equivalent) was permitted to increase the 
generalizability of results. A large portion of youth 
treated with antipsychotics are concurrently treated 
with selective serotonin reuptake inhibitors, 
stimulants, and other psychotropic medications (34). 
More specifically, the use of antipsychotics for 
treatment-resistant attention-deficit/hyperactivity 
disorder is increasingly common (35). 
 
Study Assessments 
Participants were youth between the ages of 6 and18 
years who were enrolled in the National Institute of 
Mental Health–funded “Measurement of Cardio-
metabolic Risk in Antipsychotic Treated Youth” 
study. This is a randomized controlled trial to 
evaluate metabolic changes in overweight or obese 
youth treated with antipsychotics during behavioral 
weight loss treatment as compared with obese or 
overweight but otherwise healthy controls 
undergoing the same behavioral weight loss 
treatment. All participants underwent a clinical 
evaluation by a study psychiatrist to ensure 
psychiatric stability and the appropriateness of 
continued antipsychotic treatment during study 
participation. Diagnoses were based on Diagnostic and 
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Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision criteria and corroborated with records 
of previous psychiatric treatment. A consensus study 
diagnosis was based on the preponderance of clinical 
and study data. Baseline assessments were conducted 
within one month of study enrollment, and endpoint 
assessments were conducted within two weeks of 
completing the 16-week weight loss treatment. All 
blood draws and physical study assessments were 
performed at the Washington University Pediatric 
Research Unit; imaging was performed at the Center 
for Clinical Imaging in Research and at the Nutrition 
Obesity Research Center and included the following: 
height and weight measurements performed on a 
calibrated stadiometer (Seca 240 Wall-Mounted 
Stadiometer, Germany) and scale (Seca 684 Digital 
Multifunctional Scale, Germany), respectively, by a 
trained research nurse whole body fat percentage 
measured using dual energy X-ray absorptiometry 
(Delphi W densitometer equipped with version 12.4 
software; Hologic, Waltham, MA); intrahepatic 
triglyceride content determined at baseline and at the 
study endpoint by proton magnetic resonance 
spectroscopy with a 1.5 T scanner (Magnetom 
Sonata; Seimens, Erlangen, Germany), with all 
frequencies (i.e., chemical shifts) measured relative to 
the principal water 1H resonance; and fasting plasma 
lipid (i.e., total cholesterol, low density lipoprotein 
cholesterol, high density lipoprotein cholesterol, and 
triglyceride) and glucose levels. Weekly treatment 
weights were measured on a digital office-based scale 
(Health o meter, Sunbeam Products Inc., Boca 
Raton, FL). BMI, BMI percentile, and BMI Z-score 
were calculated from medical records for each 
subject at 12 and 6 months prior to study enrollment 
and at the baseline and endpoint study assessments. 
The Washington University in St. Louis Institutional 
Review Board approved this study. 
 
Treatment Description 
FBT is an evidence-based intervention that consists 
of weekly sessions for 12 to 24 weeks and that 
includes individual family member weigh-ins, 
meetings with a trained interventionist, and separate 
parent and child groups (36). FBT targets family 
support and restructuring of the home environment 
to enable healthier behaviors while establishing self-
regulatory behaviors to promote weight manage-
ment. A weight loss goal range of 0.5 to 2 lb per week 
is set for both participating children and adults; this 
range is in line with evidence-based childhood 
obesity treatment (37) and recommenddations for 
healthy child development and weight management 
/27,38). Expected annual weight gain during normal 
growth and development varies on the basis of age 
and gender and can range from 2 to 3 lb per year in 
prepubertal and postpubertal youth to 8 to 12 lb per 
year during the prepubertal and pubertal growth 
stages, with weight gain being higher in prepubertal 
females as compared with males and higher in 
pubertal males as compared with females (39,40). For 
individuals who are already at a high weight, the 
range of 0.5 to 2 lb per week is a safe weight loss 
range for all ages and stages of growth. Core 
components of behavioral weight loss strategies 
include education about energy balance, shaping 
behaviors to promote stimulus control, and self-
monitoring. The Traffic Light Plan is used as a 
framework to help families shift their energy intake 
and expenditure with the use of a classification 
system in which the nutritional values of foods and 
the intensity values of activities are coded as RED for 
“stop and think” to indicate the least healthy options, 
YELLOW for “caution” to indicate moderately 
healthy options, and GREEN for “go” to indicate 
the healthiest options (41-44). Both participating 
parents and youths are asked to self-monitor their 
daily food intake and physical activity. Youth and 
their participating parents are asked to select from a 
list of behavioral rewards (which exclude options 
related to food or sedentary behavior) for 
accumulating points when weekly goals are met. 
Child and parent weights are measured during each 
in-person session. 
In the present case series, modifications were made 
to the existing FBT framework to facilitate delivery 
in an outpatient psychiatric treatment setting. First, 
we removed the weekly group meeting and increased 
contact with the treatment team through a mid-week 
phone check-in, and we incorporated the group 
content and skills practice into the individual family 
sessions. This was done to reduce the total time spent 
in person per week by families and interventionists 
and to allow interventionists to provide support and 
reminders to engage in self-monitoring and health 
behavior changes throughout the week. We also 
employed a simplified, one-page food and activity log 
composed of visual cues for RED and GREEN 
foods and activities. This was done to simplify food 
logging for youth who had learning disabilities or 
other cognitive challenges. We created and used a 
“taste log” to incentivize trying new GREEN and 
YELLOW foods and to promote serial 
desensitization for youth with food aversions or 
selective eating patterns. In addition, we included an 
ecological-based social facilitation component in 
each session to encourage the consolidation of health 
behavior changes across environmental contexts; we 
took into account the developmental stage of the 
participating youth, and we encouraged parents to 
facilitate the development and use of peer and 
community networks to support health behavior 
change. Weekly treatment goals were divided into 
energy balance, weight loss, and social facilitation 
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domains, and target ranges for scaled goal attainment 
were created within each domain. This allowed the 
interventionist to individualize weekly goals on the 
basis of child- and family-level characteristics and 
needs. 
 
Results 
Table 1 presents each of the three cases in detail. 
Common characteristics among participants 
included age, race, and weight related medical 
comorbidities (e.g., dyslipidemia, impaired fasting 
glucose). Additionally, each case presented unique 
parenting challenges related to either parental or 
child psychiatric considerations. Quantitative 
cardiometabolic outcomes are presented in Table 2. 
Beneficial changes in fasting total cholesterol, low 
density lipoprotein cholesterol, adiposity, and liver 
fat content were documented for Participant 1 and 
Participant 3, who both experienced greater changes 
in BMI percentile and Z-score as compared with 
Participant 2. All participants experienced a slowing 
of weight gain as compared with their pretreatment 
weight trajectories (Figure 1). No clinically significant 
changes in fasting glucose and triglyceride values 
were found. Participating parents and youth reported 
that they were either “very satisfied” (n = 2) or 
“somewhat satisfied” (n = 1) with the treatment 
program at study completion. Two parents reported 
that they would not suggest any changes to the 
treatment; one parent suggested the use of a 
computer or mobile device application for 
homework and self-monitoring. 
 
Conclusions 
Children with mental health conditions—especially 
those who are treated with antipsychotics—are 
vulnerable to developing obesity and related health 
problems. Little research has been conducted 
regarding weight loss interventions in this 
population. FBT interventions are low risk and are 
considered first-line treatments for pediatric obesity, 
with evidence for long-term sustainability (36). The 
preliminary results reported here represent, to our 
knowledge, the first reported for a behavioral weight 
loss intervention adapted for use in youth treated 
with antipsychotics. 
The primary goal of this pilot study was to 
demonstrate the feasibility of delivering a behavioral 
weight loss treatment to families of youth with 
psychiatric conditions. All participants experienced a 
beneficial change in or stabilization of their BMI 
percentile and Z-score as compared with 
pretreatment conditions, and these changes are 
similar to those of previous FBT studies (25). 
Although greater weight loss was associated with 
greater changes in metabolic parameters, it is notable 
that small reductions in weight were associated with 
measurable improvements in portions of the lipid 
panel and in liver fat content. Finally, each of the 
three cases involved a parenting component that 
challenged the family’s ability to maintain a healthy 
weight, which suggests that a family-based approach 
may be useful in this population to support parents 
who want to help their children make health behavior 
changes (Table 1).  
There are important limitations to note. As a case 
series, the sample of participants reported here was 
small and warrants continued evaluation, because the 
results may not be representative of the general 
population of children with psychiatric conditions 
who are overweight or obese. Moreover, these 
participants were adolescents, and our larger trial 
addresses both children and adolescents between the 
ages of 6 to 18 years. Estimates of children’s height 
growth patterns can be used to anticipate the weight-
for-height changes needed to achieve normal weight 
status and to guide weight loss targets on the basis of 
a youth’s age- and sex-specific BMI percentiles 
(45,46). It is important to note that our presented 
cases are adolescents with BMIs above the 99th 
percentile for age and gender at entry; children who 
are younger and closer to the 85th BMI percentile 
need to lose less weight to normalize their BMI 
percentiles as compared with youth who are older 
and who have a higher degree of obesity (46). Thus, 
the expansion of our sample to younger children 
across BMI percentiles in the overweight and obese 
ranges may provide additional information about 
treatment response and may indicate whether 
treatment for this population, which is at risk for 
continued weight gain, warrants additional 
adaptation (e.g., whether weight maintenance is more 
appropriate than weight loss for certain 
populations)(27,38,46). In addition, there may be 
important differences in an individual’s response to 
these interventions as a result of gender, ethnicity, 
age, and sociodemographic variables that are not 
represented by the individuals discussed in this case 
series.  
Selection bias can confound results in studies of 
behavior change: individuals who participate in 
research studies may be more motivated than those 
in the general population to make health behavior 
changes. Participant 1 is an example of this and may 
be quite representative of individuals with mild 
autism who also have symptoms of attention-
deficit/hyperactivity disorder; these individuals are 
commonly treated with a combination of stimulant 
and antipsychotic therapy. Although it could be 
argued that Participant 1 lost weight before starting 
the FBT as a result of concurrent stimulant therapy, 
which has a known anorectic effect, stimulants have 
not been associated with significant weight loss 
among individuals taking antipsychotics (47,48).  
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TABLE 1. Participant Characteristics and Case Description 
Participant 1 was a 14-year-old Caucasian male diagnosed with PDD-NOS1 and ADHD,2 combined type, and Learning Disorder (Reading 
and Written Expression). He had received psychiatric treatment since age 5, and at study enrollment was taking atomoxetine (Strattera) 
100 mg daily, paroxetine (Paxil) 10 mg daily and risperidone (Risperdal) 3 mg daily. Medical comorbidities related to obesity included 
impaired fasting glucose.4 Prior to study participation, food limits being set in the home resulted in aggressive behavioral outbursts. 
Treatment was tailored as follows: 
 To address parent modeling of responsive and assertive communication skills, the therapist worked with parents on how 
 to identify and anticipate behavioral triggers prior to setting limits and boundaries.  
 To address difficulties with recording foods related to learning disorder, daily family check-ins allowed the participant to 
 narrate or dictate food intake to the participating parent, while the youth utilized Traffic Light Plan materials to identify 
 nutrition data for each food item.  
Participant 2 was a 14-year-old Caucasian female diagnosed with Mood Disorder Not Otherwise Specified and GAD.3 She had received 
psychiatric treatment since age 7, and at study enrollment was taking quetiapine (Seroquel) 100 mg twice daily and 200 mg at bedtime; 
sertraline (Zoloft) 150 mg daily. Medical comorbidity related to obesity included hypercholesterolemia.5 Parental health problems, 
including limited mobility and mild cognitive impairment impacted the ability to perform key parenting skills (e.g., regular grocery 
shopping, help with completing self-monitoring logs, facilitation of conversations to promote healthy behaviors at home and with peers). 
Treatment was tailored as follows: 
 To reduce cognitive load, handouts incorporating visual cues and simplified messages regarding the primary message in 
 each meeting were utilized to reinforce session content, and the one-page food and activity log was introduced to simplify 
 self-monitoring.  
 To address parental difficulties and communication challenges, the therapists modeled adaptive communication strategies 
 and provided cues for collaborative problem solving. 
Participant 3 was a 14-year-old Caucasian male diagnosed with PDD-NOS1 and ADHD,2 combined type. He had received psychiatric 
treatment since age 3, and at study enrollment was taking osmotic-release oral system (OROS)-methylphenidate (Concerta) 54 mg daily, 
quetiapine (Seroquel) 150 mg twice daily and 100 mg at bedtime and paroxetine (Paxil) 15 mg daily. Medical comorbidity related to 
obesity included dyslipidemia.5 This youth began treatment with a significant preference for RED foods, and taste aversion to most 
GREEN foods. Parents reported weight had gradually become a problem over time because their child had limited taste preferences and 
became severely agitated when new foods were introduced. Treatment was tailored as follows: 
 To address distress about trying new foods related to sensory aversion, the interventionist worked with the family on 
 communication strategies and provided support and education about distress tolerance for parents and youth. 
 To engage the youth both during the session and during the week at home and school, a focus of therapy became 
 rewarding attempts to try new GREEN foods using the taste log.  
1 Pervasive Developmental Disorder Not Otherwise Specified 
2 Attention Deficit-Hyperactivity Disorder 
3 Generalized Anxiety Disorder 
4 Defined by American Diabetes Association Criteria (33)  
5 Defined by NCEP Expert Panel on Blood Cholesterol Levels in Children and Adolescents (34)  
 
 
 
 
 
 
TABLE 2. Changes in Metabolic Health During Study Participation 
 Participant 1 Participant 2 Participant 3 Mean 
 Baseline Endpoint Baseline Endpoint Baseline Endpoint Change (SD) 
Weight (lbs) 165.6 153.7 270.1 268.7 141.8 141.5 -4.53 (6.40) 
BMI %ile 91.13 80.94 99.48 99.41 96.16 92.69 -4.58 (5.15) 
BMI z-score 1.35 0.88 2.56 2.52 1.77 1.45 -0.28 (0.22) 
Fasting Glucose (mg/dL) 103 93 87 86 97 97 -3.67 (5.51) 
Fasting Total Cholesterol (mg/dL) 166 145 209 239 160 139 -4.00 (29.44) 
Fasting HDL Cholesterol (mg/dL) 57 62 56 60 41 38 2 (4.36) 
Fasting Triglycerides (mg/dL) 59 63 93 106 128 70 -13.67 (38.66) 
Fasting LDL Cholesterol (mg/dL) 97 70 134 158 93 87 -3 (25.63) 
DEXA Total Percent Fat 28.4 24.2 46.9 48.4 35.6 28.6 -3.23 (4.33) 
Percent Liver Fat 2.08 0.62 1.92 2.76 3.54 1.31 -0.95 (1.60) 
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FIGURE 1. Participant Weight Trajectories, 1 year Pre-Treatment and During Treatment 
 
 
 
 
A more likely cause of weight loss before beginning 
treatment is the motivation for behavioral change. 
After observing the pretreatment weight trajectory 
for Participant 1, we modified our study timeline to 
allow only 2 weeks between baseline testing and 
starting FBT. Finally, although the potential 
mechanisms of antipsychotic-related weight gain can 
be surmised from receptor binding profiles, future 
studies should evaluate the neurobiological changes 
associated with antipsychotic treatment and weight 
loss treatment to develop more effective and 
individualized weight loss interventions.  
 
Clinical Significance 
Our findings demonstrates that a minimally modified 
FBT intervention can be feasibly delivered to youth 
with psychiatric disorders and could be disseminated 
via clinical settings in which weekly encounters with 
behavioral health providers can occur (e.g., 
community mental health centers). Although 
beneficial changes were noted in liver fat, whole body 
adiposity, fasting total cholesterol, and low density 
lipoprotein cholesterol levels, definitive conclusions 
regarding the effectiveness of this intervention 
cannot be made on the basis of the results of these 
first three participants. Further study is needed to 
more definitively determine treatment effectiveness, 
to clearly identify population- and diagnosis-specific 
challenges to weight loss, and to determine the most 
effective strategies for personalizing treatment and 
mobilizing family member support to promote 
weight loss success. 
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